Last reviewed · How we verify
LYB005 low dose without adjuvant — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
LYB005 low dose without adjuvant (LYB005 low dose without adjuvant) — Guangzhou Patronus Biotech Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LYB005 low dose without adjuvant TARGET | LYB005 low dose without adjuvant | Guangzhou Patronus Biotech Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LYB005 low dose without adjuvant CI watch — RSS
- LYB005 low dose without adjuvant CI watch — Atom
- LYB005 low dose without adjuvant CI watch — JSON
- LYB005 low dose without adjuvant alone — RSS
Cite this brief
Drug Landscape (2026). LYB005 low dose without adjuvant — Competitive Intelligence Brief. https://druglandscape.com/ci/lyb005-low-dose-without-adjuvant. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing